GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » ROE %

Pharmaron Beijing Co (HKSE:03759) ROE % : 7.28% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pharmaron Beijing Co's annualized net income for the quarter that ended in Mar. 2024 was HK$1,002 Mil. Pharmaron Beijing Co's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was HK$13,758 Mil. Therefore, Pharmaron Beijing Co's annualized ROE % for the quarter that ended in Mar. 2024 was 7.28%.

The historical rank and industry rank for Pharmaron Beijing Co's ROE % or its related term are showing as below:

HKSE:03759' s ROE % Range Over the Past 10 Years
Min: 8.13   Med: 13.98   Max: 34.61
Current: 12.43

During the past 10 years, Pharmaron Beijing Co's highest ROE % was 34.61%. The lowest was 8.13%. And the median was 13.98%.

HKSE:03759's ROE % is ranked better than
91.85% of 1349 companies
in the Biotechnology industry
Industry Median: -43.73 vs HKSE:03759: 12.43

Pharmaron Beijing Co ROE % Historical Data

The historical data trend for Pharmaron Beijing Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co ROE % Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.80 14.51 17.75 12.70 13.73

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.07 15.25 11.93 15.25 7.28

Competitive Comparison of Pharmaron Beijing Co's ROE %

For the Biotechnology subindustry, Pharmaron Beijing Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's ROE % distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's ROE % falls into.



Pharmaron Beijing Co ROE % Calculation

Pharmaron Beijing Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=1751.245/( (11779.794+13734.359)/ 2 )
=1751.245/12757.0765
=13.73 %

Pharmaron Beijing Co's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=1001.82/( (13734.359+13782.003)/ 2 )
=1001.82/13758.181
=7.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Pharmaron Beijing Co  (HKSE:03759) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=1001.82/13758.181
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1001.82 / 11604.92)*(11604.92 / 28191.114)*(28191.114 / 13758.181)
=Net Margin %*Asset Turnover*Equity Multiplier
=8.63 %*0.4117*2.049
=ROA %*Equity Multiplier
=3.55 %*2.049
=7.28 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=1001.82/13758.181
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (1001.82 / 1167.204) * (1167.204 / 1359.512) * (1359.512 / 11604.92) * (11604.92 / 28191.114) * (28191.114 / 13758.181)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8583 * 0.8585 * 11.71 % * 0.4117 * 2.049
=7.28 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pharmaron Beijing Co ROE % Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (HKSE:03759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc 2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd. 2301 Trustee
Kastle Limited 2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you

Pharmaron Beijing Co (HKSE:03759) Headlines

No Headlines